Polarean Imaging PLC (LON:POLX) CEO Richard Hullihen tells Proactive its two phase III clinical trials have 'demonstrated handily' that its technology allows doctors and surgeons to visualize aspects of lung function that have gone undetected using traditional magnetic resonances imaging (MRI) techniques. Hullihen says Polarean expects to submit a new drug application (NDA) for its drug/device in the third quarter, after a pre-NDA meeting with the FDA.
Full interview: Polarean Imaging achieves positive phase III results in two clinical trials
Quick facts: Polarean Imaging PLC
Price: 35 GBX
Market Cap: £56.64 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Polarean Imaging PLC named herein, including the promotion by the Company of Polarean Imaging PLC in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE